Orion regains certain rights for Parkinson's disease drug Stalevo

4 December 2018

Finnish drugmaker Orion Corp (Nasdaq OMX: ORNAV) and Swiss pharma giant Novartis (NOVN: VX) have agreed that Novartis will return the sales and distribution rights in certain European countries for Parkinson's disease drug Stalevo (levodopa, carbidopa, entacapone).

The sales and distribution rights in certain European countries for the proprietary product Stalevo, which has been patented and developed by Orion for the treatment of Parkinson's disease, transfer from Novartis to Orion as of December 3, 2018.

Central nervous system (CNS) disorders are one of Orion's three core therapy areas, and, measured by net sales, Parkinson's disease drugs are Orion's largest family of pharmaceutical preparations. Stalevo has been on the market since 2003.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK